Measuring the difference we make – a word from our director
This year, we reshaped our annual brokerage event. As well as looking ahead to Calls 14 and 15, we took time to reflect on what the programme has achieved so far, what our projects are delivering, and how partnerships address the bigger questions facing Europe: how we support uptake in healthcare systems, strengthen patient and civil society participation, and respond to Europe’s competitiveness challenges.
Collectively, there was a clear sense that in health innovation, success cannot be measured by industrial capability alone. It must also be judged by the difference we make to health, equity and wellbeing, and by whether innovation is understood, trusted and taken up in practice.
That message came through strongly in the panels, but what really struck me was how the early careers session captured this in practice. The posters and presentations brought the value of partnership, with contributions from across sectors and disciplines showing how collaboration leads to better science and new insights. Together, they offered a remarkable snapshot of Europe’s research capacity. View them all on the IHI website.
There is now a new opportunity to be part of this community. This month, we published the draft topic texts for next year, and Calls 14 and 15 will open in January. As always, the preliminary topic texts are published as we send them for consultation with our governance groups. If you are thinking about getting involved, now is the time to start shaping ideas and building consortia.
Niklas Blomberg, IHI Executive Director
Collectively, there was a clear sense that in health innovation, success cannot be measured by industrial capability alone. It must also be judged by the difference we make to health, equity and wellbeing, and by whether innovation is understood, trusted and taken up in practice.
That message came through strongly in the panels, but what really struck me was how the early careers session captured this in practice. The posters and presentations brought the value of partnership, with contributions from across sectors and disciplines showing how collaboration leads to better science and new insights. Together, they offered a remarkable snapshot of Europe’s research capacity. View them all on the IHI website.
There is now a new opportunity to be part of this community. This month, we published the draft topic texts for next year, and Calls 14 and 15 will open in January. As always, the preliminary topic texts are published as we send them for consultation with our governance groups. If you are thinking about getting involved, now is the time to start shaping ideas and building consortia.
Niklas Blomberg, IHI Executive Director
Catch up on the IHI Forum 2026
Our IHI Forum 2026 highlighted the power of the public-private partnership model as a tool to bring diverse stakeholders together to tackle challenges across the entire continuum of care. The event also showcased the work of early career researchers in IMI and IHI projects. The recordings of the plenary sessions, plus the pdfs of the posters, are available on the event web page.
Read the draft topic texts for calls 14 and 15
The draft topics cover non-animal approaches, personalised healthtech, ATMP manufacture, compassionate use, and more. The calls are scheduled for launch in early 2027.
Join the webinar: In conversation with SOPHIA
How can we better predict who will respond best to treatments for obesity? SOPHIA developed an algorithm to do exactly that, meaning fewer unnecessary interventions for patients.
Register for the event
Non-profit providing tools to investigate childhood cancer receives 100 enquiries
ITCC-P4 gGmbH’s models of tumours of childhood cancers are much-needed and in high demand from both industry and academia.
The patients missing from clinical research
Clinical studies do not always accurately reflect the people who will ultimately receive new treatments. Researchers across Europe are exploring how to close the gaps and make clinical research more representative and inclusive.
Could the evolution of multi-drug resistant bacteria also be their downfall?
Multi-drug resistant bacteria evolve rapidly to withstand aggressive antibiotic treatments. But COMBACTE-MAGNET showed that sometimes, these evolutions may result in trade-offs that can be exploited to kill the bacteria.
PFAROS aims to give PFAS the push
The new project’s goal is to accelerate the move away from harmful PFAS substances in healthcare in Europe.